chartexchange

Phathom: 3 Key Takeaways for Long-Term Investors

The Motley Fool | Nov 18, 2026 3:45 PM EST

On its third-quarter 2026 earnings call, held on Oct. 29, 2026, Phathom (NASDAQ:PHAT) announced net revenues of $84.7 million for the quarter. The biopharmaceutical company is turning revenue growth into cash flow while expanding coverage for VOQUEZNA, its treatment for gastroesophageal reflux disease, or GERD. Management shares three takeaways on how the business is executing. Phathom shifted its sales focus to educate physicians on prior authorization, which is health plan approval before coverage, and driving prescriptions through its partner pharmacy, BlinkRx. To boost fulfillment rates, it introduced a $0 copay offering through BlinkRx for eligible commercially insured patients. Continue reading

Read original article